Australia's most trusted
source of pharma news
Posted 30 November 2021 AM
A white paper commissioned by Biogen has made 32 recommendations to improve treatment for Alzheimer's Disease (AD), including training nurses and pathology centres to administer disease modifying therapies (DMTs) if and when they become available.
Information resources about DMTs for primary care providers to support them should also be developed, the paper suggested. Biogen's Aduhelm is currently before the TGA, and the company hopes to hear the outcome in the first half of 2022.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.